PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'School of Basic Medicine, Peking Union Medical College, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, China.\', \'Department of Radiation and Medical Oncology, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China.\', \'Hubei Cancer Clinical Study Center, Zhongnan Hospital, Wuhan University, Wuhan, China.\', \'National Cancer Center/Cancer Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.\', \'Guangdong Provincial Key Laboratory of Single Cell Technology and Application, School of Basic Medical Science, Southern Medical University, Guangzhou, China.\', \'Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430000, China. Chenyeshan2014@163.com.\', \'Department of Radiation and Medical Oncology, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China. chxie_65@whu.edu.cn.\', \'Hubei Cancer Clinical Study Center, Zhongnan Hospital, Wuhan University, Wuhan, China. chxie_65@whu.edu.cn.\', \'Department of Thoracic Surgery, TongJi Hospital, TongJi Medical College, Huazhong University of Science and Technology, Wuhan, 430000, China. Wuxiaowei20@126.com.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1038/s41598-021-96195-w
?:doi
?:hasPublicationType
?:journal
  • Scientific reports
is ?:pmid of
?:pmid
?:pmid
  • 34462453
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.533
?:rankingScore_hIndex
  • 122
is ?:relation_isRelatedTo_publication of
?:title
  • Durable tracking anti-SARS-CoV-2 antibodies in cancer patients recovered from COVID-19.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all